Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Barcelona, Spain, 1 September 2009: Asymptomatic or mildly symptomatic cardiac patients randomised to an implanted cardiac resynchronisation device with defibrillator (CRT-D) have a 34% lower risk of heart failure or death than those receiving a standard implanted cardioverter defibrillator (ICD-only) (HR 0.66, p=0.001), according to results from the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) study.
The MADIT-CRT study was a randomised trial designed to determine if CRT-D therapy would reduce the primary endpoint (all-cause mortality or heart failure events, whichever occurred first) when compared to patients receiving ICD-only therapy. The study population involved cardiac patients in New York Heart Functional Class I or II (no or mild symptoms) who had either ischaemic or non-ischaemic heart disease with left ventricular dysfunction (ejection fraction <30%) and QRS duration of >130ms on ECG.
Cardiac resynchronisation therapy (CRT) with or without a defibrillator is indicated for use in patients with severe heart failure (New York Heart Association Class III/IV), and CRT has been shown to reduce symptoms, mortality and hospitalisation in very sick cardiac patients. The question that remained was whether CRT would improve heart function and slow or prevent the development of heart failure in the less severe NYHA class I/II cardiac patients (moderately high risk, but with no or mild symptoms) by intervening early in the course of the disease before the development of advanced symptoms.
The MADIT-CRT trial enrolled and followed 1820 patients from 110 centers in Europe, Canada, and the USA during a 4.5-year period between December 2004 and 22 June 2009, when the trial was officially ended because of the superiority of the cardiac resynchronisation therapy (p=0.001). Patients were randomised in a 3:2 fashion to receive either CRT-D or ICD alone, and all patients received optimal medical therapy for heart failure during the trial.
The superiority of CRT-D therapy was found to be present in all patient sub-groups, including those with ischaemic and non-ischaemic types of heart disease, as well as in males and females, younger and older patients, and those with mild and more advanced heart dysfunction.
Commenting on the results, the study’s principal investigator, Professor Arthur J Moss from the University of Rochester Medical Center, New York, USA, said: “Cardiac resynchronisation therapy was dramatically effective in this large study population, with a 34% reduction in the risk of all-cause mortality or heart failure. The benefit is dominated by a 41% reduction in heart failure events. This results validate a new indication for cardiac resynchronisation therapy in the prevention of heart failure in at-risk asymptomatic or mildly symptomatic cardiac patients. It seems likely that this preventive CRT-D therapy will have widespread application and utilisation.”
- Ends -
This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2009. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology.
© 2017 European Society of Cardiology. All rights reserved